Astellas adds muscle disease, ophthalmology TAs

Astellas Pharma Inc. (Tokyo:4503) released a new three-year strategic plan that adds muscle diseases and ophthalmology as therapeutic areas. The company's innovative medicines strategy for FY15-17 also will include development of next-generation vaccines and cell therapies to treat cardiovascular disease and cancer.

The announcement comes about two years after the Japanese pharma said it would restructure R&D and focus on accessing earlier stage assets via partnerships (see BioCentury, June 17, 2013). ...